<?xml version="1.0" ?>
<tei xml:space="preserve">
	<teiHeader>
		<fileDesc xml:id="Meltzer 2009"/>
	</teiHeader>
	<text xml:lang="en">
		<front>
<lb/>
	<docTitle>
	<titlePart>Burden of allergic rhinitis: Results from the Pediatric<lb/> Allergies in America survey<lb/></titlePart>
	</docTitle>

	<byline>
	<docAuthor>Eli O. Meltzer, MD, a Michael S. Blaiss, MD, b M. Jennifer Derebery, MD, c Todd A. Mahr, MD, d Bruce R. Gordon, MD, e<lb/> Ketan K. Sheth, MD, f A. Larry Simmons, MD, g Mark A. Wingertzahn, PhD, h and John M. Boyle, PhD i San Diego and<lb/></docAuthor>
	</byline>

	<byline>
	<affiliation>Los Angeles,</affiliation>
	</byline>

	<address>Calif, Memphis, Tenn, La Crosse, Wis, Hyannis, Mass, Lafayette, Ind, Little Rock, Ark, Florham Park, NJ, and New York, NY<lb/></address>

	<div type="abstract">Allergic rhinitis (AR), a chronic inflammatory disease of the<lb/> upper airway, is one of the most common chronic diseases in the<lb/> United States and is estimated to affect up to 60 million people.<lb/> Pediatric Allergies in America is the largest and most<lb/> comprehensive survey to date of pediatric patients and parents of<lb/> patients with allergy, as well as health care providers (HCPs),<lb/> regarding AR in children and its treatment. The goals of the<lb/> survey were to determine the prevalence of AR in the US<lb/> pediatric population and to collect information on what effect the<lb/> condition has on patients in terms of symptom burden, quality of<lb/> life, productivity, disease management, and pharmacologic<lb/> treatment. This national survey screened 35,757 households to<lb/> identify 500 children with HCP-diagnosed nasal allergies and 504<lb/> children without nasal allergies who were between the ages of 4<lb/> and 17 years. Parents of young children, as well as children 10 to<lb/> 17 years of age, were questioned about the condition and its<lb/> treatment. In parallel, 501 HCPs were interviewed. This survey<lb/> has captured previously unavailable data on the prevalence of<lb/> nasal allergies and their most common and most bothersome<lb/> symptoms, on the effect of nasal allergies on the quality of life of<lb/> children, and on medication use, including both over-the-counter<lb/> and prescription medications, and has identified factors affecting<lb/> satisfaction with treatment. The Pediatric Allergies in America<lb/> survey also identifies distinct areas for improvement in the<lb/> management of AR in children. In fact, based on the results of this<lb/> survey, it appears that HCPs overestimate patients&apos; and parents&apos;<lb/> satisfaction with disease management and the benefit of<lb/> medications used for the treatment of nasal allergies in children.<lb/> Findings from this national survey have identified important<lb/> challenges to the management of AR, suggesting that its burden<lb/> on children in the United States has been significantly<lb/> underestimated.</div>

	(J Allergy Clin Immunol 2009;124:S43-70.)<lb/> Key words:
	<keyword>Allergic rhinitis, nasal allergies, pediatric allergy,<lb/> prevalence, burden, intranasal corticosteroids<lb/></keyword>

	From a the Allergy and
	<byline>
	<affiliation>Asthma Medical Group and Research Center,</affiliation>
	</byline>

	<address>San Diego;</address>

	<byline>
	<affiliation>b the<lb/> University of Tennessee Health Sciences Center,</affiliation>
	</byline>

	<address>Memphis;</address>

	<byline>
	<affiliation>c the House Ear Clinic,<lb/></affiliation>
	</byline>

	<address>Los Angeles;</address>

	<byline>
	<affiliation>d Gundersen Lutheran Medical Center, Pediatric Allergy/Immunology,<lb/></affiliation>
	</byline>

	<address>La Crosse;</address>

	<byline>
	<affiliation>e Cape Cod Ear, Nose, and Throat Specialists, Hyannis; f Lafayette Allergy<lb/> and Asthma Clinic,</affiliation>
	</byline>

	<address>Lafayette;</address>

	<byline>
	<affiliation>g the University of Arkansas for Medical Sciences, Ar-<lb/>kansas Children&apos;s Hospital,</affiliation>
	</byline>

	<address>Little Rock;</address>

	<byline>
	<affiliation>h Nycomed US, Florham Park; and i Schulman,<lb/> Ronca and Bucuvalas, Inc,</affiliation>
	</byline>

	<address>New York.<lb/></address>

	<note type="funding">Supported by Nycomed US. Support for editorial assistance was provided by Nycomed<lb/> US, and Sepracor Inc.<lb/></note>

	Disclosure of potential conflict of interest: E. O. Meltzer received grant support from<lb/>
	<meeting>Alcon, Amgen, Antigen, Apotex, AstraZeneca, Boehringer Ingelheim, Capnia, Clay-<lb/>Park, Critical Therapeutics, Genentech, GlaxoSmithKline, Hoffmann-LaRoche, MAP<lb/> Pharmaceuticals, Medicinova, Meda, Merck, Naryx, Novartis, Nycomed US, Phar-<lb/>maxis, Rigel, Sanofi-Aventis, Schering-Plough, Skye Pharma, Teva, Vocel, and Wyeth;<lb/> is a consultant for Abbott, Alcon, Allux, Amgen, AstraZeneca, Capnia, Critical<lb/> Therapeutics, Dey, Evolutec, Genentech, GlaxoSmithKline, Greer, Inspire, Meda,<lb/> Merck, Novartis, Nycomed US, Pfizer, Rigel, Sanofi-Aventis, Schering-Plough,<lb/> Sepracor, Shionogi, VentiRx, and Wyeth; is a speaker for AstraZeneca, Alcon,<lb/> Genentech, GlaxoSmithKline, Meda, Merck, Pfizer, Sanofi-Aventis, Schering</meeting>

	<note type="funding">-Plough,<lb/> and Sepracor; has provided expert witness testimony on allergic rhinitis and asthma.<lb/> M. S. Blaiss is a consultant and speaker for Sepracor, Nycomed, GlaxoSmithKline,<lb/> Schering Plough, Alcon, AstraZeneca, Genentech, Teva, Merck, Sanofi-Aventis, UCB,<lb/> Proctor and Gamble; receives grant support from UCB and GlaxoSmithKline, and has<lb/> provided legal consultation/expert witness testimony in cases related to asthma. M. J.<lb/> Derebery is a speaker for Sepracor, GlaxoSmithKline, Schering Plough, Meda, and<lb/> Alcon; is an advisor for SRxA; and received grant support from Alcon. T. A. Mahr is on<lb/> the speakers&apos; bureau for Alcon, AstraZeneca, Genentech, GlaxoSmithKline, Merck,<lb/> Novartis, Sanofi-Aventis, Schering-Plough, and UCB; receives grant support from<lb/> Alcon, AstraZeneca, Genentech, and GlaxoSmithKline, serves on the committees for<lb/> the American College of Allergy, Asthma &amp; Immunology, the American Academy of<lb/> Allergy, Asthma &amp; Immunology, and for the American Academy of Pediatrics; is on<lb/> the board for American Lung Association-Wisconsin; and is on the executive commit-<lb/>tee for the Wisconsin Asthma Coalition. B. R. Gordon has provided legal consultation/<lb/> expert witness testimony in cases related to anaphylaxis, and is a consultant and/or<lb/> speaker for ALK-Abello, Merck, Sanofi-Aventis, and Schering-Plough. Previously<lb/> published research (not including this research), has been funded by the University<lb/> of Singapore and by the American Academy of Otolaryngic Allergy Foundation.<lb/></note>

	<div type="abstract">Dr Gordon has no relevant business, patent, or stock ownership issues. None of these<lb/> relationships represent any material or significant conflict of interest to his<lb/> participation in the Pediatric Allergies in America study. K. K. Sheth is a consultant<lb/> for Alcon, GlaxoSmithKline, Nycomed, is a member of the speakers bureau for<lb/> Sanofi-Aventis and GlaxoSmithKline, and serves on a committee for the American<lb/> College of Allergy, Asthma &amp; Immunology. A. L. Simmons is an advisory board con-<lb/>sultant for Nycomed, and is an advisory board consultant on the speakers&apos; bureau for<lb/> GlaxoSmithKline. M. A. Wingertzahn is employed by Nycomed. J. M. Boyle is<lb/> Executive Vice President of Abt SRBI, which conducted the survey under a contract<lb/> from HealthStar Communications. Abt SRBI also had a contract from ProEd Commu-<lb/>nications for additional analyses after the HealthStar contract was completed.<lb/> Disclosure of sponsor involvement: In any sponsored investigation the issue of bias is<lb/> invariably of concern for the pharmaceutical company and the authors, as well as for<lb/> the journal&apos;s reviewers and readers. During the conduct of this study, much effort was<lb/> made to mitigate potential bias, and safeguards were put in place to limit the sponsor&apos;s<lb/> participation. The Pediatric Allergies in America survey was designed by a panel of<lb/> experts within the allergy and ear, nose, and throat specialties. The sponsor had<lb/> negligible input during these meetings, except for stating that it had hoped the project<lb/> would study the current magnitude of the prevalence and burden of nasal allergies. This<lb/> limited sponsor involvement was not an attempt to shape or otherwise influence the<lb/> direction or outcome of the survey. The survey questions, in concert with the expert<lb/> panel, were written by and administered through Abt SRBI, a respected global strategy,<lb/> public policy, and opinion polling organization that has as clients multiple Fortune 500<lb/> companies; federal, state, and local governments; foundations; and universities. Data<lb/> from the survey were not revealed to the sponsor before a follow-up meeting that was<lb/> held with the clinician advisory committee, thus further minimizing any risk of sponsor<lb/> bias of the data. Finally, the authorship includes only 1 person from the sponsoring<lb/> company, Dr Wingertzahn, a PhD within their clinical development department. Dr<lb/> Wingertzahn has a solid foundation in ethical research and has authored numerous<lb/> manuscripts in peer-reviewed journals within the area of allergy. He was not a member<lb/> of the core writing committee but was a reviewer of the supplement. We believe that<lb/> pharmaceutical companies, no less than clinicians, are appropriately interested in<lb/> learning as much as possible about the needs of their market and patients.<lb/></div>

	<note type="submission">Received for publication August 4, 2008; revised April 29, 2009; accepted for publication<lb/> May 11, 2009.<lb/></note>

	Reprint requests:
	<byline>
	<docAuthor>Eli O. Meltzer, MD, Allergy and Asthma</docAuthor>
	</byline>

	<byline>
	<affiliation>Medical Group and Research<lb/> Center,</affiliation>
	</byline>

	<address>9610 Granite Ridge Dr, Suite B, San Diego, CA 92123.</address>

	E-mail:
	<email>eomeltzer@<lb/> aol.com</email>

	.<lb/> 0091-6749/$36.00<lb/>
	<note type="copyright">Ã“ 2009 American Academy of Allergy, Asthma &amp; Immunology<lb/></note>

	<idno>doi:10.1016/j.jaci.2009.05.013<lb/></idno>

	Abbreviations used<lb/> AR: Allergic rhinitis<lb/> HCP:
	<note type="submission">Health care provider<lb/> INCS: Intranasal corticosteroid<lb/> ISAAC: International Study of Asthma and Allergies in Childhood<lb/> NHANES: National Health and Nutrition Examination Survey<lb/> NP: Nurse practitioner<lb/> OTC: Over the counter<lb/> PA: Physician assistant<lb/> QoL: Quality of life<lb/> URI: Upper respiratory tract infection<lb/> J ALLERGY CLIN IMMUNOL<lb/> SEPTEMBER 2009<lb/></note>

	FIG 1. (Continued)
		</front>
	</text>
</tei>
